Pharmaceutical intermediates
Tenapanor Hydrochloride Intermediates
4 pharmaceutical intermediates for Tenapanor Hydrochloride. Indication: Hyperphosphatemia; chronic renal insufficiency; constipation; irritable bowel syndrome.
About Tenapanor Hydrochloride
- Originator
- Ardelyx, Inc
- Indication
- Hyperphosphatemia; chronic renal insufficiency; constipation; irritable bowel syndrome
- Approved Date
- 09/12/2019
- DS/DP
- 12/30/2029
Available intermediates
4 intermediates currently listed for Tenapanor Hydrochloride. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Isoquinoline, 4-(3-bromophenyl)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-, (4S)- | 1870821-29-6 | / | / |
| 4-(3-bromophenyl)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline | 543737-10-6 | / | / |
| Boc-1-amino-3,6-dioxa-8-octanediamine | 153086-78-3 | / | / |
| (2,4-Dichlorobenzyl)methylamine | 5013-77-4 | / | / |
Building toward Tenapanor Hydrochloride?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →